Document is current
Any future updates will be listed below
-
Authors
Zeng, Jing
Wu, Yuxuan
Ren, Chunyan http://orcid.org/0000-0002-3913-2479
Bonanno, Jasmine
Shen, Anne H.
Shea, Devlin
Gehrke, Jason M.
Clement, Kendell http://orcid.org/0000-0003-3808-0811
Luk, Kevin
Yao, Qiuming
Kim, Rachel
Wolfe, Scot A. http://orcid.org/0000-0002-7042-201X
Manis, John P.
Pinello, Luca
Joung, J. Keith
Bauer, Daniel E. http://orcid.org/0000-0001-5076-7945
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (P01HL053749)
National Institute of Allergy and Infectious Diseases (R01AI117839)
National Institute of General Medical Sciences (R01GM115911, R35 GM118158)
National Human Genome Research Institute (R00HG008399, RM1 HG009490)
-
License Information
Text and Data Mining valid from 2020-03-16
Version of Record valid from 2020-03-16
-
More Information
Article History
Received: 30 August 2019
Accepted: 4 February 2020
First Online: 16 March 2020
Competing interests
: The authors declare competing financial interests; details are available in the online version of the paper. J.K.J. has financial interests in Beam Therapeutics, Editas Medicine, Excelsior Genomics, Pairwise Plants, Poseida Therapeutics, Transposagen Biopharmaceuticals and Verve Therapeutics (f/k/a Endcadia). J.K.J.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. J.K.J. is a member of the Board of Directors of the American Society of Gene and Cell Therapy. J.M.G. and J.K.J. are co-inventors on a patent application describing the A3A (N57Q) BE3 variant used in this study. J.K.J. is also a co-inventor on various patents and patent applications that describe gene editing, base editing and epigenetic editing technologies. J.Z., Y.W., and D.E.B. are co-inventors on various patents related to therapeutic gene editing technologies.
